Treatment Experiences with CDK4&6 Inhibitors Among Women with Metastatic Breast Cancer: A Qualitative Study

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.21590
   PubMed Web of Science ®Google Scholar
• O’Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist. 2005;10(Suppl 3):20–29. doi:10.1634/theoncologist.10-90003-20
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. SEER cancer stat facts: female breast cancer. Available from: https://seer.cancer.gov/statfacts/html/breast.html. Accessed August 17, 2021.
   Google Scholar
• Mariotto AB, Etzioni R, Hurlbert M, Penberthy L, Mayer M. Estimation of the Number of Women Living with Metastatic Breast Cancer in the United States. Cancer Epidemiol Biomarkers Prev. 2017;26(6):809–815. doi:10.1158/1055-9965.EPI-16-0889
   PubMed Web of Science ®Google Scholar
• The American Cancer Society medical and editorial content team. Treatment of Stage IV (Metastatic) Breast Cancer. American Cancer Society; 2020. Available from: https://www.cancer.org/cancer/breast-cancer/treatment/treatment-of-breast-cancer-by-stage/treatment-of-stage-iv-advanced-breast-cancer.html. Accessed August 25, 2020.
   Google Scholar
• Garcia-Aranda M, Redondo M. Protein Kinase Targets in Breast Cancer. Int J Mol Sci. 2017;18(12):2543. doi:10.3390/ijms18122543
   Web of Science ®Google Scholar
• Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305(5682):399–401. doi:10.1126/science.1099480
   PubMed Web of Science ®Google Scholar
• The American Cancer Society medical and editorial content team. Targeted therapy for breast cancer. American cancer society.; 2020. Available from: https://www.cancer.org/cancer/breast-cancer/treatment/targeted-therapy-for-breast-cancer.html. Accessed August 25, 2020.
   Google Scholar
• Borner M, Scheithauer W, Twelves C, Maroun J, Wilke H. Answering patients’ needs: oral alternatives to intravenous therapy. Oncologist. 2001;6(Suppl 4):12–16.
   PubMed Web of Science ®Google Scholar
• Spoelstra SL, Given BA, Given CW, et al. Issues related to overadherence to oral chemotherapy or targeted agents. Clin J Oncol Nurs. 2013;17(6):604–609. doi:10.1188/13.CJON.17-06AP
   Web of Science ®Google Scholar
• Given BA, Spoelstra SL, Grant M. The challenges of oral agents as antineoplastic treatments. Semin Oncol Nurs. 2011;27(2):93–103. doi:10.1016/j.soncn.2011.02.003
   PubMedGoogle Scholar
• Verbrugghe M, Verhaeghe S, Lauwaert K, Beeckman D, Van Hecke A. Determinants and associated factors influencing medication adherence and persistence to oral anticancer drugs: a systematic review. Cancer Treat Rev. 2013;39(6):610–621. doi:10.1016/j.ctrv.2012.12.014
   PubMed Web of Science ®Google Scholar
• Jacobs JM, Ream ME, Pensak N, et al. Patient experiences with oral chemotherapy: adherence, symptoms, and quality of life. J Natl Compr Canc Netw. 2019;17(3):221–228. doi:10.6004/jnccn.2018.7098
   PubMed Web of Science ®Google Scholar
• Greer JA, Amoyal N, Nisotel L, et al. A systematic review of adherence to oral antineoplastic therapies. Oncologist. 2016;21(3):354–376. doi:10.1634/theoncologist.2015-0405
   PubMed Web of Science ®Google Scholar
• Sikorskii A, Given CW, Given BA, et al. An Automated Intervention Did Not Improve Adherence to Oral Oncolytic Agents While Managing Symptoms: results From a Two-Arm Randomized Controlled Trial. J Pain Symptom Manage. 2018;56(5):727–735. doi:10.1016/j.jpainsymman.2018.07.021
   PubMed Web of Science ®Google Scholar
• Huang WC, Chen CY, Lin SJ, Chang CS. Medication adherence to oral anticancer drugs: systematic review. Expert Rev Anticancer Ther. 2016;16(4):423–432. doi:10.1586/14737140.2016.1159515
   PubMed Web of Science ®Google Scholar
• Mathes T, Pieper D, Antoine SL, Eikermann M. Adherence influencing factors in patients taking oral anticancer agents: a systematic review. Cancer Epidemiol. 2014;38(3):214–226. doi:10.1016/j.canep.2014.03.012
   PubMed Web of Science ®Google Scholar
• Lin C, Clark R, Tu P, Bosworth HB, Zullig LL. Breast cancer oral anti-cancer medication adherence: a systematic review of psychosocial motivators and barriers. Breast Cancer Res Treat. 2017;165(2):247–260. doi:10.1007/s10549-017-4317-2
   PubMed Web of Science ®Google Scholar
• Streeter SB, Schwartzberg L, Husain N, Johnsrud M. Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions. Am J Manag Care. 2011;17(Suppl 5):Sp38–44.
   Web of Science ®Google Scholar
• Gast A, Mathes T. Medication adherence influencing factors-an (updated) overview of systematic reviews. Syst Rev. 2019;8(1):112. doi:10.1186/s13643-019-1014-8
   PubMed Web of Science ®Google Scholar
• Messina C, Messina M, Zanardi E. Risks and benefits from CDK inhibitors for advanced HR+ Her 2- breast cancer. Ann Oncol. 2017;28(12):3099–3100. doi:10.1093/annonc/mdx530
   Web of Science ®Google Scholar
• Messina C, Cattrini C, Buzzatti G, et al. CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials. Breast Cancer Res Treat. 2018;172(1):9–21. doi:10.1007/s10549-018-4901-0
   PubMed Web of Science ®Google Scholar
• Li J, Huo X, Zhao F, et al. Association of cyclin-dependent kinases 4 and 6 inhibitors with survival in patients with hormone-receptor positive metastatic breast cancer: a systematic review and meta-analysis. JAMA Network Open. 2020;3(10):e2020312. doi:10.1001/jamanetworkopen.2020.20312
   PubMed Web of Science ®Google Scholar
• Martin JM, Goldstein LJ. In support of CDK 4/6 inhibitors - A meta-analysis of available randomized data. JAMA Network Open. 2020;3(10):e2021062. doi:10.1001/jamanetworkopen.2020.21062
   Web of Science ®Google Scholar
• Baird J, Bowen K, Gleason P. Palbociclib (Ibrance®) Utilization and Costs among 18 Million Insured Americans: managed Care Pharmacy Opportunities. presented at: AMCP: Orlando, FL, USA; 2015.
   Google Scholar
• Guest G, Bunce A, Johnson L. How Many Interviews Are Enough? Field Methods. 2016;18(1):59–82. doi:10.1177/1525822x05279903
   Web of Science ®Google Scholar
• Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat. 2012;134(2):459–478. doi:10.1007/s10549-012-2114-5
   PubMed Web of Science ®Google Scholar
• Atkinson TM, Rodríguez VM, Gordon M, et al. The Association Between Patient-Reported and Objective Oral Anticancer Medication Adherence Measures: a Systematic Review. Oncol Nurs Forum. 2016;43(5):576–582. doi:10.1188/16.Onf.576-582
   Web of Science ®Google Scholar
• Singhal M, Nepal B, Fisch M et al. Treatment Patterns Including Adherence/Persistence With Cyclin-Dependent Kinase 4&6 Inhibitors (CDK4&6i) Among US Commercially Insured Women With Metastatic Breast Cancer (mBC). presented at: Virtual ISPOR Europe 2020: Milan, Italy. Value in Health, 23; 2020, Issue S2, PCN221.
   Google Scholar
• Kimmick G, Edmond SN, Bosworth HB, et al. Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy. Breast. 2015;24(5):630–636. doi:10.1016/j.breast.2015.06.010
   PubMed Web of Science ®Google Scholar
• Babcock A, Ali AA, Balkrishnan R, Montero A, Diaby V. Real-World Clinical and Economic Outcomes Associated with Palbociclib for HR-Positive/HER2 Negative Metastatic Breast Cancer: a Commentary. J Manag Care Spec Pharm. 2020;26(7):826–831. doi:10.18553/jmcp.2020.26.7.826
   PubMed Web of Science ®Google Scholar
• Geynisman DM, Meeker CR, Doyle JL, et al. Provider and patient burdens of obtaining oral anticancer medications. Am J Manag Care. 2018;24(4):e128–e133.
   PubMed Web of Science ®Google Scholar
• Zafar SY, Peppercorn J, Asabere A, Bastian A. Transparency of Industry-Sponsored Oncology Patient Financial Assistance Programs Using a Patient-Centered Approach. J Oncol Pract. 2017;13(3):e240–e248. doi:10.1200/jop.2016.017509
   Web of Science ®Google Scholar
• Zullig LL, Wolf S, Vlastelica L, Shankaran V, Zafar SY. The Role of Patient Financial Assistance Programs in Reducing Costs for Cancer Patients. J Manag Care Spec Pharm. 2017;23(4):407–411. doi:10.18553/jmcp.2017.23.4.407
   Web of Science ®Google Scholar
• Farano JL, Kandah HM. Targeting Financial Toxicity in Oncology Specialty Pharmacy at a Large Tertiary Academic Medical Center. J Manag Care Spec Pharm. 2019;25(7):765–769. doi:10.18553/jmcp.2019.25.7.765
   PubMed Web of Science ®Google Scholar
• Olszewski AJ, Zullo AR, Nering CR, Huynh JP. Use of Charity Financial Assistance for Novel Oral Anticancer Agents. J Oncol Pract. 2018;14(4):e221–e228. doi:10.1200/JOP.2017.027896
   PubMed Web of Science ®Google Scholar